drugset / Trial / NCT05733598
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2027-12-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | RP2 | Other / unclassified | — | Other |